BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Sep 24, 2019
Financial News

Amphivena to expand clinical program, T cell engager pipeline with $62M series C

Amphivena Therapeutics Inc. will use its $62 million series C to advance its lead candidate in solid tumors and build out its T cell engager portfolio. The round, closed Tuesday, was co-led by new investors...
BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
BC Week In Review | Oct 12, 2018
Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
BC Extra | Oct 9, 2018
Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
Items per page:
1 - 10 of 91
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

The U.K.'s NICE said Gillian Leng will become chief executive, effective April 1, succeeding Andrew Dillon, who is stepping down. Leng was NICE's deputy chief executive and director of health and social care. Separately, the...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Sep 24, 2019
Financial News

Amphivena to expand clinical program, T cell engager pipeline with $62M series C

Amphivena Therapeutics Inc. will use its $62 million series C to advance its lead candidate in solid tumors and build out its T cell engager portfolio. The round, closed Tuesday, was co-led by new investors...
BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
BC Week In Review | Oct 12, 2018
Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Oct. 9 after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The...
BC Extra | Oct 9, 2018
Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product...
Items per page:
1 - 10 of 91